ANIX (Anixa Biosciences) Marketable Securities: $12.21 Mil (As of Apr. 2026)


ANIX Anixa Biosciences Inc ANIX
27 GF Score
Price $3.21
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences Marketable Securities?

Anixa Biosciences ANIX +3.54% 27 Marketable Securities is $12.21 Mil as of Apr. 2026. GuruFocus rates ANIX with a GF Score™ of 27/100. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Anixa Biosciences's Marketable Securities for the quarter that ended in Apr. 2026 was $12.21 Mil.

Anixa Biosciences's annual Marketable Securities declined from Oct. 2023 ($22.93 Mil) to Oct. 2024 ($18.65 Mil) and declined from Oct. 2024 ($18.65 Mil) to Oct. 2025 ($13.93 Mil).

Anixa Biosciences  (NAS:ANIX) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Anixa Biosciences Marketable Securities Related Terms

Anixa Biosciences Marketable Securities Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences Marketable Securities Chart

Anixa Biosciences Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.60 17.33 22.93 18.65 13.93

Anixa Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.69 14.53 13.93 12.66 12.21
ANIX
27GF Score
Anixa Biosciences Inc ANIX
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $12.21 Mil mean?
Anixa Biosciences (ANIX) has a Marketable Securities of $12.21 Mil as of Apr. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Anixa Biosciences and its competitors.
Is Anixa Biosciences' Marketable Securities too high?
Anixa Biosciences' current Marketable Securities is $12.21 Mil. Overall, Anixa Biosciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' Marketable Securities compare to BMEA and PMN?
Anixa Biosciences' Marketable Securities of $12.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Anixa Biosciences and its competitors. Anixa Biosciences's current Marketable Securities is $12.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current Marketable Securities of $12.21 Mil. The current Marketable Securities is $12.21 Mil. Anixa Biosciences' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current Marketable Securities is $12.21 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anixa Biosciences Business Description

Other Exchanges CY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
27GF Score

Get the complete analysis for ANIX

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.21
Price